• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Acerta Pharma - Articles and news items

Orphan drug designation recommended for acalabrutinib in three indications

Industry news / 25 February 2016 / Victoria White

The COMP has recommended the orphan drug designation for acalabrutinib in chronic lymphocytic leukaemia, mantle cell lymphoma and lymphoplasmacytic lymphoma…


Webinar: NIR Spectroscopy for Assessing Blend Uniformity in the Pharmaceutical IndustryLEARN MORE
+ +